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Abstract
Background: Efficacy and safety of anticancer drugs are traditionally studied using cancer cell lines and animal
models. The thienodiazepine class of BET inhibitors, such as JQ1, has been extensively studied for the potential
treatment of hematological malignancies and several small molecules belonging to this class are currently under
clinical investigation. While these compounds are well known to inhibit cancer cell growth and cause apoptosis,
their effects on stem cells, particularly mesenchymal stem cells (MSCs), which are important for regeneration of
damaged cells and tissues, are unknown. In this study we employed umbilical cord derived MSCs as a model
system to evaluate the safety of JQ1.
Methods: Cord derived MSCs were treated with various doses of JQ1 and subjected to cell metabolic activity, apoptosis,
and cell cycle analyses using MTT assay, Annexin-V/FITC and PI staining, and flow cytometry, respectively. The effect of
JQ1 on gene expression was determined using microarray and quantitative real-time reverse transcriptase polymerase
chain reaction analysis. Furthermore, protein expression of apoptotic and neuronal markers was carried out using
western blot and immunostaining, respectively.
Results: Our results showed that JQ1 inhibited cell growth and caused cell cycle arrest in G1 phase but did not induce
apoptosis or senescence. JQ1 also down-regulated genes involved in self-renewal, cell cycle, DNA replication, and
mitosis, which may have negative implications on the regenerative potential of MSCs. In addition, JQ1 interfered with
signaling pathways by down regulating the expression of WNT, resulting in limiting the self-renewal. These results
suggest that anticancer agents belonging to the thienodiazepine class of BET inhibitors should be carefully evaluated
before their use in cancer therapy.
Conclusions: This study revealed for the first time that JQ1 adversely affected MSCs, which are important for repair and
regeneration. JQ1 specifically modulated signal transduction and inhibited growth as well as self-renewal. These findings
suggest that perinatal MSCs could be used to supplement animal models for investigating the safety of anticancer
agents and other drugs.
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Background
Recently, bromo- and extra-terminal domain (BET) pro-
tein inhibition has emerged as a therapeutic target for
cancer, metabolic disorders, and inflammatory diseases
[1–3]. BET proteins contain two related bromodomain
(BD) motifs, BD1 and BD2, located at the amino acid
terminal region, and one extra-terminal (ET) domain
located either at the carboxyl terminal region of the
short isoform and protein members or at the central
region of the long isoform and protein members. The
two BDs facilitate binding to the BET protein acetylated
lysine residues on the histone tail, while the ET domain
recruits transcription and epigenetic regulatory factors
[3–7]. In mammals, there are four members belonging
to the BET protein subfamily: BRD2, BRD3, BRD4, and
BRDT. BET proteins have been shown to play vital roles
in the pathogenesis of specific leukemia and viral associ-
ated cancers such as Kaposi sarcoma and cervical
cancers [1, 3, 5, 7]. BRD2 has been shown to play a role
in rheumatoid arthritis while BRD4 is implicated in im-
mune diseases through regulation of nuclear factor-κB-
dependent genes in response to an activated innate
immune system and regulation of macrophage primary
responsive genes [8]. Consequently, BET proteins have
been targeted for controlling cancerous cell growth.
Several small molecules belonging to the thienodiaze-
pine group that inhibit BET proteins [1–3, 5, 7, 8] have
been developed. Four such molecules (I-BET 762, OTX-
015, TEN-010, and CPI-0610) have been approved as an-
ticancer agents for clinical trials [9, 10]. More recently
another such small molecule, JQ1 ((S)-tert-butyl 2-(4-(4-
chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]tria-
zolo[4,3-a][1,4]diazepin-6-yl)acetate), has been shown to
have high specificity against BET proteins. JQ1 functions
by displacing the BET proteins from the acetylated lysine
residues and inhibiting their activities. Chromosomal
translocation of BRD3 and BRD4 has been shown to
contribute to pathogenesis of the NUT (nuclear protein
in testis) midline carcinoma (NMC) [2, 4, 6]. Treatment
of NMC with JQ1 resulted in G1 cell cycle arrest, apop-
tosis, and differentiation [11]. Recently, the effects of
JQ1 have been studied in various cancerous cell lines
and animal models [12–15]. These studies showed that
JQ1 inhibits BRD4 function, which leads to cell cycle
arrest and promotion of apoptosis in multiple myeloma
cells, leukemia and lymphoma cells, and neuroblastoma
cells by downregulating expression of translocated c-MYC
which is involved in their pathogenesis [12, 14, 15]. JQ1
has also been shown to decrease proliferation and induce
apoptosis in NF1-associated malignant peripheral nerve
sheath tumors [13]. Similar observations have been shown
in DNMT3A (DNA methyltransferase 3A) mutated
leukemia where JQ1 inhibits the action of BRD4 and in-
duces caspase 3/7-mediated apoptosis [16]. Moreover, JQ1
has been shown to be an effective drug to treat STAT5
(Signal transducer and activator of transcription 5) associ-
ated leukemia and lymphoma through inhibition of BRD2
function [17].
Although JQ1 and other members of the thienodiaze-
pine class of BET inhibitors are well investigated using
cancerous cells, their effect on normal cells—particularly
adult stem cells such as mesenchymal stem cells
(MSCs)—has not been investigated to our knowledge.
Cord-derived MSCs are more primitive and display
greater self-renewal potential compared with MSCs
derived from adult sources. Unlike MSCs from adult
sources such as bone marrow MSCs, cord-derived MSCs
can be expanded to provide sufficient amount of cells
for experimentation. Therefore, we selected cord-derived
MSCs as a model system to investigate the effects of
JQ1. We hypothesized that JQ1 could affect cell growth
and gene expression of normal stem cells such as MSCs
differently to its known effects on cancer cells. In this
study, we showed that JQ1 induced cell cycle arrest in
the G1 phase of MSCs, but unlike cancer cells did not
promote apoptosis. We found JQ1 also downregulated
genes involved in self-renewal, mitosis, and DNA repli-
cation. We propose that human MSCs could be used in
addition to animal models to investigate the safety of
anticancer agents; because MSCs play a significant role
in tissue repair and regeneration, findings from this
investigation may be directly relevant to humans.
Methods
Culture of MSCs
Human umbilical cord samples were obtained from con-
sented healthy donors through the Beaumont Hospital
BioBank and isolation of MSCs was carried out at Oak-
land University (Rochester, MI, USA) under approved
protocols (HIC# 2012-101 and IRB# 400244, respectively).
Human umbilical cord-derived MSCs were isolated and
characterized in our laboratory. Briefly, the region
between the cord and placenta was dissected, minced into
approximately 1–2 mm pieces, and cultured in 75 cm2
culture flasks using growth medium (GM) containing
Dulbecco’s modified Eagle’s (DMEM) with 4500 mg/ml
glucose and 2 mML-glutamine (Invitrogen, Carlsbad, CA,
USA), supplemented with 10 % fetal bovine serum
(Aleken Biologicals, Nash, TX, USA), and antibiotic solu-
tion (0.1 % gentamicin, 0.2 % streptomycin, and 0.12 %
penicillin) (Sigma Aldrich, St. Louis, MO, USA). The
culture medium was changed every 3 days until cells grew
to 70 % confluency from explants. Cells were dissociated
using TrypLE Select (Invitrogen), passaged in the GM to
passage 3, characterized using flow cytometry (BD Canto II,
analyzed by FACS Canto II; BD Biosciences, San Jose, CA,
USA) and differentiated to multilineage. Adherent cells
displaying fibroblastoid morphology and positive for CD44,
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CD90, CD73, CD29, and CD105 and negative for CD34
and CD45 in accordance with the ISCT standards [18] were
considered MSCs and used in this study.
Treatment of MSCs with JQ1
MSCs (passages 8–10) were seeded onto 0.1 % gelatin-
coated culture plates, and propagated in GM at 37 °C in
an atmosphere of 5 % CO2 in a humidified incubator
overnight. Cells were then treated with various concen-
trations ranging from 0 to 500 nM JQ1 (Brander’s
Laboratory, Harvard Medical School, Boston, MA,
USA). JQ1 was dissolved in dimethyl sulfoxide (DMSO;
Thermo Fisher Scientific, Waltham, MA, USA).
Cell viability and proliferation assays
MSCs (2.5 × 104 cells/25 cm2 flasks) were grown overnight
and treated with 0, 10, 100, and 500 nM JQ1 for 24 and
72 hours. Cells were dissociated with TrypLE, centrifuged,
and resuspended in trypan blue solution for counting by
hemocytometer. Cells stained blue were considered nonvi-
able cells. The samples were analyzed in triplicate.
Cell proliferation and metabolic activity was determined
by direct counting using the hemocytometer and MTT
assay, respectively. For the MTT assay, cells were cultured
in 24-well plates overnight and then incubated with
500 μg/ml MTT reagent (Sigma, St. Louis, MO, USA) at
37 °C for 2 hours to obtain blue formazan crystals. The
formazan complex was solubilized by adding 150 μl
isopropanol/HCl (15:1) to each well and the absorbance
was determined at 570 nm using an Epoch Microplate
Spectrophotometer (BioTek, Winooski, VT, USA).
Immunocytochemistry assay
MSCs grown in GM containing 0 and 500 nM JQ1 for
5 days were rinsed with phosphate-buffered saline (PBS)
and fixed with 4 % paraformaldehyde for 10 minutes at
room temperature. Cells were washed with PBS, and then
permeabilized with 0.5 % TritonX100 in PBS for
10 minutes. They were then washed twice with PBS
followed by incubation with 2 % bovine serum albumin in
PBS to block nonspecific binding for 30 minutes at room
temperature. After blocking, cells were incubated in TUJ1
and MAP2 primary antibodies (diluted 1:50; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) overnight at 4 °C.
Next, cells were washed three times with PBS for
5 minutes each time and were incubated in Cy3-
labeled goat anti-mouse IgG and fluorescein isothiocyan-
ate (FITC)-labeled goat anti-rabbit IgG (diluted 1:200;
KPL, Gaithersburg, MD, USA), respectively, for 1 hour at
room temperature, washed three times with PBS for
5 minutes each time, incubated with 4′,6-diamidino-2-
phenylindole (DAPI; diluted 1:100) for nucleic acid stain-
ing for 10 minutes, and visualized by fluorescence micros-
copy (NIKON Instruments Inc., Melville, NY, USA).
Apoptosis analysis
MSCs (1 × 106 cells) were cultured in 75 cm2 flasks in
GM overnight. Cells were exposed to 0, 10, 100, or 500
nM JQ1 for 24 and 72 hours. Cells were then harvested
by dissociating with TrypLE, pelleted by centrifugation,
washed with PBS, and resuspended in PBS. Cell suspen-
sions were stained with Annexin V/FITC and propidium
iodide (PI) according to the manufacturer’s instructions
(Biolegend, San Diego, CA, USA). Briefly, PBS-washed
cells were suspended in 100 μl FITC binding buffer at a
minimum concentration of 1 × 106 combined with 5 μl
Annexin V/FITC and 10 μl PI (Sigma). After 15 minutes
of incubation in the dark on ice, cells were centrifuged
at 2000 rpm for 10 minutes, resuspended in PBS, and
analyzed by FACSCanto II. Cells that were Annexin V-
negative and PI-negative were considered viable cells. Cells
positive for Annexin V only were considered apoptotic,
and cells positive for PI only were considered necrotic or
late apoptotic. All samples were prepared in triplicate.
Cell cycle analysis
MSCs (1 × 106 cells) were cultured in 75 cm2 flasks in
GM overnight. Cells were exposed to DMSO and 0, 10,
100, or 500 nM JQ1 for 24 and 72 hours. Treated cells
were harvested and fixed with 70 % ice-cold ethanol
overnight at 4 °C. Control and treated cells were incubated
with 1 mg/ml PI solution (Sigma), 0.5 % TritonX100,
RNase, and PBS at room temperature in the dark for
20 minutes. Cells were then washed and resuspended in
PBS. The DNA content was assessed using FACS Canto II
and the results were analyzed using ModFit software
(Verity Software House, Topsham, ME, USA). All samples
were prepared in triplicate.
Microarray analysis
MSCs (1 × 106 cells) were cultured in 75 cm2 flasks in
GM overnight. Cells were treated with 0, 100, and 500
nM JQ1 for 24 hours. RNA was isolated from frozen cell
pellets using the E.Z.N.A. Total RNA Kit I (Omega,
Norcross, GA, USA). RNA was purified using spin cart-
ridge technology, quantified (Nanodrop 8000; Thermo
Scientific), and stored at –80 °C. RNA was then ampli-
fied and labeled using the TargetAmp-Nano Labeling Kit
(Epicenter, Madison, WI, USA) which enables amplifica-
tion and target preparation compatible with the Direct
Hybridization Assay (Illumina, San Diego, CA, USA).
Amplification was performed with 500 ng total RNA input
following procedures described in the TargetAmp-Nano
Labeling Kit user guide. Hybridization and staining to the
HumanHT-12 v4 Expression BeadChip (Illumina) was
performed using 750 ng biotin-antisense RNA product
following protocols outlined in the Whole-Genome Gene
Expression Direct Hybridization Assay Guide (Illumina).
Subsequent scanning of the BeadChip was performed
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using the iScan System (Illumina). Gene expression data
were imported into Illumina Genome Studio (v2011.1)
and subsequently analyzed in Partek Genomics Suite,
Partek Inc. , St. Louis, MO, USA (6.6 version 6.14.0828).
The accession number for the microarray data reported is
[NCBI GEO:GSE705770].
Quantitative reverse transcriptase PCR
Total cellular mRNA was isolated using the GeneJET
RNA purification Kit (Thermo Fisher Scientific), following
the manufacturer’s instructions. Total RNA was purified
by incubation with DNase at 37 °C for 30 minutes using a
thermocycler (MJ Research PTC-100 Thermal Cycler;
GMI, Ramsey, MN, USA). cDNA was synthesized using
the BioRad iScript kit (Bio-Rad, Hercules, CA, USA).
Quantitative reverse transcriptase PCR (qRT-PCR) was
performed using 10 μl reaction volume containing 5 μl
Syber green (Sso-Advanced Universal SYBR Green Super-
mix Kit; Bio-Rad), 3 μl distilled H2O, 0.5 μl forward
primer, 0.5 μl reverse primer, and 1 μl of 1:10 diluted
cDNA on the CFX96 Real-Time System (Bio-Rad). Each
reaction was subjected to the following conditions: 98 °C
for 10 minutes, followed by 44 cycles of 98 °C for 30 sec-
onds, 60 °C for 20 seconds, and 72 °C for 30 seconds in
96-well optical reaction plates (Bio-Rad). The reference
gene GAPDH was used to normalize the amplification
of the target genes. Each qRT-PCR analysis was per-
formed in triplicate. Primer sequences are listed in
Additional file 1.
Western blotting
Cells were treated with 0 and 500 nM JQ1 for 72 hours.
Protein was extracted by lysing the cells in RIPA buffer
with PMSF (Sigma). Then 10 μl total proteins were sepa-
rated with SDS-PAGE with 12 % resolving gel and 6 %
stacking gel. Samples were diluted in sample diluting
buffer, heated at 95 °C for 5 minutes, and loaded on to
the gel and electrophoresed. Proteins were then electro-
phoretically transferred onto Polyvinylidene difluoride
(PVDF) membrane for 1 hour at 150 mA constant
current. The membrane was blocked with 5 % nonfat
dry milk for 1 hour at room temperature and then incu-
bated overnight at 4 °C with primary antibodies for
Caspase-8, Caspase-9, and β-actin (Santa Cruz Biotech-
nology) diluted 1:50 in blocking solution. The membrane
was washed to remove unbound primary antibody and
was incubated with secondary antibody (1:1000 dilution;
Santa Cruz Biotechnology) in blocking solution for
1 hour at 37 °C. Unbound secondary antibody was
washed with PBS containing 0.1 % Tween-20. Blots were
developed with chemiluminescence system (Bio-Rad),
and exposed to X-ray film (FUJI Film, Tokyo, Japan).
Band intensity was quantified with ImageJ software,
(NIH, Bethesda, MD, USA).
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM). Results with p ≤0.05 were considered sta-
tistically significant. All analyses were performed using
SPSS (Chicago, IL, USA) version 11.5 (SPSS Inc., USA).
Results
Effect of JQ1 on growth of MSCs
MSCs isolated from umbilical cord had fibroblastoid
morphology (Fig. 1a) and were positive for the MSC
specific surface markers CD90, CD73, CD44, CD105,
and CD29, as shown in Fig. 1b. These MSCs exhib-
ited self-renewal and, unlike cancer cells, were cap-
able of differentiation into various lineages. An ideal
anticancer drug would inhibit growth or promote
apoptosis of cancer cells, but not normal cells, par-
ticularly stem cells and progenitors such as MSCs.
While JQ1 is well known to cause growth inhibition
and apoptosis induction in cancer cells, its effect on
normal cells is not well understood. Our studies with
JQ1 showed that it affected the morphology of MSCs
(Fig. 1c) and caused significant reduction in cell prolifera-
tion at the 500 nM dose. When MSCs were treated with
500 nM for 7 days, cells appeared to be significantly
larger and flatter than the control cells (Fig. 1d), sug-
gesting cell differentiation. Further analysis of the
JQ1-treated cells showed a dose-dependent effect of
JQ1 on MSC proliferation (Fig. 1e, f ). Evidently, the
metabolic activity of MSCs was decreased at 100 and
500 nM JQ1, but not at 10 nM JQ1. In fact, a lower dose
of 10 nM JQ1 promoted cell proliferation 24 hours after
treatment.
Changes in the morphology of the JQ1-treated MSCs
were further quantified by flow cytometry. Cell size and
granularity increased in a concentration and time-
dependent manner (Fig. 2a). Exposure of cells to 100
nM and 500 nM JQ1 for 24 hours resulted in increased
cell size in 6 % and 12 % of the populations, respectively,
without noticeable effect on the cellular granularity.
When the cells were exposed to 100 nM and 500 nM
JQ1 for 5 days, both size and granularity were increased
in 52 % and 57 % of the cell populations, respectively
(Fig. 2b). Although loss of CD90, CD73, CD44, and
CD29 was insignificant, CD105 was lost in 22 % and
24 % of MSCs treated with 100 nM and 500 nM JQ1,
respectively, for 5 days (Fig. 2c, d).
To test the effect of JQ1 on cell cycle progression, cell
cycle analysis was performed on the JQ1-treated MSCs
and the results depicted in Fig. 3 show that 100 nM and
500 nM doses of JQ1 had 10 % and 12 % increase in cells
arrested in G1 phase, respectively. Conversely, the number
of cells in the S phase was decreased in a dose-dependent
manner. However, no significant change was observed in

























































































Fig. 1 (See legend on next page.)
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the percentage of cells in the G2/M phase in MSCs treated
with JQ1. These results suggested that JQ1 induced G1
phase cell cycle arrest in MSCs.
Analysis of genes involved in cell cycle regulation in
JQ1-treated MSCs
To investigate the global effect of JQ1 on gene expression
in MSCs, microarray analysis was performed on cells
treated with 0, 100 and 500 nM JQ1 for 24 hours. Results
showed that 2134 genes were differentially upregulated or
downregulated; 445 of them were differentially expressed
with p ≥0.01 (210 genes were expressed within 1.5-fold
cutoff values and 53 at 2-fold cutoff values) (Fig. 4a, b).
Further analysis showed that one of the highly regulated
groups of genes was those which are involved in cell cycle
regulation, including CCNA2, CCNB2, CDC2, and E2F2
genes (Fig. 4c). In addition, several genes involved in DNA
replication and regulation of mitosis and cell division,
such as TOP2A, CDCA8, NEK2, CENPF, CENPA, PBK,
and AURKB, as well as genes involved in senescence such
as RB2, CDKN1A, CDKN2A, and CDKN1B, were signifi-
cantly downregulated.
Downregulation of these genes in MSCs treated with 100
and 500 nM JQ1 for 24 hours was further investigated by
qRT-PCR. Results depicted in Fig. 5 showed that 100 nM
JQ1 caused a 3-fold to 9-fold decrease in CCNA2, CDK1,
E2F2, and CCNB2 transcription in comparison with the
control, and 500 nM JQ1 led to more than a 9-fold de-
crease in the transcription of these genes (Fig. 5a). Further-
more, the transcriptional levels of CCND1, CDK6, c-MYC,
and RB1 were found to be downregulated 4-fold to 9-fold
compared with control when examined by qRT-PCR.
Among these genes, c-MYC transcription was downregu-
lated 8-fold, while the transcription of CCND1 decreased
5-fold to 6-fold in JQ1-treated cells. CDK6 transcription,
however, was downregulated by 8-fold to 9-fold. RB1 tran-
scription also decreased in a dose-dependent manner from
4-fold to 8-fold as shown in Fig. 4a. Moreover, 500 nM
JQ1 caused significant reduction (approximately 9-fold) in
the transcription of TOP2A, CDCA8, NEK2, and CENPF
(Fig. 5b). Taken together, these results showed downregula-
tion of genes involved in cell cycle regulation.
Effect of JQ1 on cell apoptosis
MSCs treated with JQ1 had no observable cell death. To
further investigate whether JQ1 induced apoptosis in
MSCs, Annexin V-treated cells were analyzed by flow
cytometry. These results, as depicted in Fig. 6a, showed
that JQ1 treatment for up to 72 hours had no significant
increase in apoptotic cell population. These cells were also
analyzed for expression of genes involved in regulation of
apoptosis including antiapoptotic BCL2, proapoptotic
BIM, and initiator Caspases 8 and 9. Results showed that
mRNA expression levels of BCL2, Caspase 8 and Caspase
9 were reduced significantly by 6-fold to 9-fold while no
significant change in the mRNA expression of BIM was
observed (Fig. 6b). Further investigation by western blot
analysis indicated that levels of proapoptotic proteins such
as Caspase 8 and Caspase 9 were reduced in JQ1-treated
cells in comparison with the control (Fig. 6c, d). However,
the reduction in expression of Caspase 9 was less pro-
nounced (Fig. 6d). These results suggested that MSCs did
not undergo apoptosis in response to JQ1.
Effect of JQ1 on expression of genes involved in WNT
signaling and differentiation
To test whether JQ1 induces the differentiation of MSCs,
microarray data indicated downregulation of genes in-
volved in self-renewal (Fig. 4c). Significant downregulation
of Oct4, Nanog, Sox2, and Klf4 markers in MSCs treated
with JQ1 was confirmed by qRT-PCR (Fig. 7a). This led us
to look at the WNT signaling pathway, which is involved
in regulating the genes involved in self-renewal and differ-
entiation. Downregulation of WNTgenes is known to indi-
cate decreased self-renewal and increased differentiation.
Determination of the transcriptional level of WNT genes
showed that WNT4, WNT5a, and WNT11 were not
expressed in MSCs and were not affected by JQ1. However,
the expression ofWNT2, a member of the canonical WNT
pathway, was decreased by 8.5-fold and 9.5-fold in MSCs
treated with 100 nM and 500 nM JQ1, respectively, com-
pared with control. This is in agreement with the micro-
array analysis, which showed that the expression of FZD2,
a WNT receptor involved in the canonical WNT pathway,
and WNT2 were also downregulated in JQ1-treated cells
(See figure on previous page.)
Fig. 1 Characterization of cord-derived MSCs and effect of JQ1 on their growth. a Phase contrast image of the cord-derived MSCs showing fibroblastoid
morphology. Images acquired at 4× magnification. b Flow cytometric analysis for cell specific surface markers. Cord-derived MSCs were positive for MSC
markers CD90, CD73, CD44, CD105, and CD29 and negative for hematopoietic stem cell markers CD34 and CD45. c Effect of JQ1 on cell morphology.
Phase contrast images of cells treated with 0, 10, 100, and 500 nM for 24 hours a–d and for 72 hours e–h. Images acquired at 4× magnification. d Light
micrographic images of cells treated with 0 nM a and 500 nM b JQ1 when cultured for 7 days. Images acquired at 10× magnification.
MSCs lost fibroblastoid morphology and grew larger in size upon exposure to JQ1. e Effect of JQ1 on growth rate. JQ1 at concentrations
of 100 and 500 nM resulted in a significant decrease in cell growth in comparison with the control cells in a time-dependent manner,
while 10 nM showed no effect on cellular growth at 24 hours but showed significant increase at 72 hours. f Effect of JQ1 on cell metabolic activity as
determined using the MTT assay. JQ1 at a concentration of 500 nM resulted in significant decrease in cell growth in comparison with the control cells,
while 10 nM showed no effect on cellular growth. *p ≤0.05. FITC fluorescein isothiocyanate, JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate



















































Fig. 2 (See legend on next page.)
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(Fig. 4c). Further analysis revealed downregulation of
FZD4 but a 2-fold upregulation of FZD6 and LRP6 com-
pared with the control. In addition, WNT-related proteins
CTNNB1 and AXIN were upregulated by 2-fold and 6-
fold, respectively. Taken together, these results suggest JQ1
modulated signal transduction by turning off WNT
pathway resulting in downregulation of pluripotent
genes and induction of differentiation (Fig. 7b). These
results prompted us to explore the transcription levels
of lineage-specific differentiation markers. Results depicted
in Fig. 7c showed that osteogenic markers Col1 and Runx2,
and chrondrogenic markers Col2 and Sox9, were
(See figure on previous page.)
Fig. 2 Exposure to JQ1 caused an increase in MSC size with simultaneous loss of CD105. Cells were treated with 0, 100, and 500 nM JQ1 for 24 hours
and 5 days and were subjected to FACs analysis. a Plots displaying size and granularity of cells. Both size and granularity of cells were increased in a
concentration and time-dependent manner. b Quantification of percentage of cell populations changed in cell size upon exposure to JQ1. c CD105
loss was proportional to concentration of JQ1. d Quantification of the MSC surface markers of JQ1 upon 5 days of exposure. *p ≤0.05. All plots are
representative of three biological experiments. JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate,



































Fig. 3 JQ1 arrested MSCs in the G1 phase of the cell cycle. Cell cycle profile of MSCs treated with DMSO and 0, 10, 100, and 500 nM JQ1 for 24 hours,
stained with PI. Mean cell population percentage ± SEM (n = 3). Analysis was performed using ModFit software (Verity Software House, Topsham, ME,
USA). Shown are histogram and graphical representations of cells in the G0/G1, S, and G2/M phases of cell cycle (a and b, respectively). *p ≤0.05.
DMSO dimethyl sulfoxide, JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate
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Fig. 4 Microarray analysis of MSCs treated with JQ1. Pie charts showing the percentage of differentially expressed genes in JQ1-treated MSCs at
different fold cutoff values at p ≤0.05 a and p ≤0.01b. c Heatmap depicting highly upregulated (red) and downregulated (blue) genes, in MSCs
treated with 0, 100, and 500 nM JQ1 for 24 hours. Zoomed-in downregulated genes (left) and upregulated genes (right)
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downregulated. Interestingly, Nestin was downregulated
but TUJ1, CCL5, INA, and SMURF2 were significantly up-
regulated (Fig. 7d). Microarray data were also in agreement
with qRT-PCR results showing upregulation of all these
genes. Furthermore, immunocytochemical analysis con-
firmed the expression of these specific proteins, TUJ1 and
MAP2 (Fig. 7e). While expressions of these genes are gen-
erally associated with neuronal differentiation, additional
studies will be required to show a direct effect of JQ1 on
differentiation of MSCs.
Discussion
A number of chemicals have been developed and investi-
gated for their anticancer properties, such as cell cycle
arrest or cell death of cancer cells [4, 6]. Potential anti-
cancer agents are typically tested in cultured cancer cells
and animal models [19]. Studying the safety of antican-
cer agents in animal models has limitations because the
results may not be directly applicable to humans due to
genetic and physiological differences. For instance, only
one-third of drugs tested using animal models pass onto
clinical trials [20]. For these reasons, it is important to
develop alternative methods, which have greater predict-
ability and are less expensive to test safety and efficacy
of new drugs. In this study, we use MSCs isolated from
human umbilical cord tissue as a model system to test
the safety of a potential anticancer agent, JQ1, which has
been extensively investigated in animal models and vari-
ous cancer cell lines [11, 12, 14]. It has been shown that
JQ1, used in concentrations ranging from 100 nM to
1 μM, exerted anticancer activities in cancer cell lines
through the inhibition of BET proteins, and conse-
quently alteration in the transcription of target genes
which play pivotal roles in the progression of cancerous
diseases [21–23]. However, its effect on normal stem
cells such as MSCs, which are involved in repair and
regeneration of damaged tissues, is poorly studied both
in vivo and in vitro.
Fig. 5 Downregulation of genes in MSCs treated with 100 and 500 nM JQ1 for 24 hours. a qRT-PCR analysis of transcripts of cell cycle genes
including CCNA2, CCNB2, CCND1, CDK1, CDK6, E2F2, c-MYC, and RB1. b DNA replication and mitosis genes including CDCA8, CENPF, NEK2, and
TOP2A. *p ≤0.05. Ctrl control, JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate
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Fig. 6 Effect of JQ1 on apoptosis of MSCs. a Annexin V/FITC and PI staining of MSCs treated with 0, 10, 100 and 500 nM JQ1 for 24 and 72 hours.
Plots are representative of the mean number of Annexin V-positive cells (n = 3) from three biological experiments. b qRT-PCR analysis of apoptosis
genes including BCL2, BIM, Caspase 8, and Caspase 9 c. *p ≤0.05. c Western blotting showing downregulation of Caspase 8 and Caspase 9 in MSCs
treated with 500 nM JQ1. d Caspase 8 and 9 expression was quantified by ImageJ software and normalized to β-actin expression. Ctrl control, FITC
fluorescein isothiocyanate, JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate, PI
propidium iodide
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Fig. 7 (See legend on next page.)
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Our study showed that JQ1 affected cell morphology
and inhibited proliferation of cord-derived MSCs. This ob-
servation was consistent with the growth inhibition caused
by JQ1 in various cancer cell lines derived from NMC,
multiple myeloma, leukemia, and neuroblastoma [11–15].
JQ1 caused increases in cell size and granularity with sim-
ultaneous loss of CD105, suggesting differentiation of
MSCs. Loss of CD105 has been implicated in the differen-
tiation of cord blood-derived MSCs [24]. To explore the
mechanism of growth inhibition of MSCs, we performed
cell cycle analysis on MSCs treated with JQ1. Cell cycle
profiles of JQ1-treated cells showed an increase in the per-
centage of cells arrested in the G1 phase, but a decrease in
the percentage of cells in the S phase. These results indi-
cated that JQ1 adversely affected cell cycle progression in
MSCs. These observations are in agreement with previous
studies in which JQ1 has been reported to induce G1 cell
cycle arrest in many cancer cells, including nerve sheath
tumors and leukemic cell lines [6, 17].
Previous studies with cancer cells have shown that JQ1
binds to BET proteins and inhibits their interaction with
acetylated histones, causing cell cycle arrest in the G1
phase and apoptosis [11, 12]. Furthermore, JQ1 also
downregulates key genes involved in control of the
cell cycle and upregulates genes involved in apoptosis
[14, 15, 17, 25]. Therefore, we questioned whether
genes involved in cell cycle regulation and apoptosis
were affected by JQ1 in MSCs as well.
Microarray analysis of JQ1-treated MSCs pointed to
cell cycle arrest in the G1 phase. Microarray data con-
firmed by qRT-PCR analyses showed that a number of
genes involved in cell cycle regulation, including CCNA2,
CCNB2, CCND1, CDK1, CDK6, c-MYC, and E2F2, were
downregulated. CCNA2 interacts with CDK2, and their
activity starts late in the G1 phase and lasts through the S
and G2 phases [26, 27]. BRD2 has been shown to activate
the transcription of CCNA2 through binding to its pro-
moter [28, 29]. Downregulation of CCNA2 in our study is
consistent with the observation that overexpression of
BRD2 upregulated the transcription of CCNA2 which led
to aggressive cancer in the mouse [30]. Also, a BRD2 mu-
tation resulted in loss of CCNA2 transcriptional activation
in NIH3T3 cells [31, 32]. CCND1 and CCND2 are known
to play a role in G1/S transition, and they associate with
their partners CDK4 and CDK6 during cell cycle regula-
tion [33, 34]. Cyclin D is required to drive the cell cycle
through the transcription activation of Cyclin A and
Cyclin E. As such, they are connected to many cancers
through their overexpression or the interruption of their
pathways [35]. Studies showed that JQ1 or BRD4 knock-
down in NF1 (Neurofibromatosis type 1)-associated ma-
lignant peripheral nerve sheath tumors decreased the
expression of CCND1 [16]. A similar effect was observed
upon treatment of medulloblastoma cell lines with JQ1
[36]. The effect of JQ1 on MSCs in our study, as well as
on cancer cell lines in the other studies, are in line with
the previous studies showing that BRD4 activates the tran-
scription of CCND1 and CCND2, and that their expres-
sion is reduced in NIH3T3 cells after knockdown of BRD4
[33]. BRD2 also has been shown to regulate the tran-
scription of CCND1 [28, 29]. c-MYC is an oncogene
that is expressed early in the G1 stage and has a crucial
role in cell cycle progression [37]. It is known to activate
the transcription of proliferation genes, and overexpres-
sion is associated with tumorigenesis [36, 38–40]. c-MYC
has been shown to be regulated by BRD4 in various can-
cer cell lines such as Hela cells and leukemia cells, and c-
MYC expression was reduced upon BRD4 knockdown or
cell treatment with small molecules inhibiting BRD4 [14,
37]. JQ1 is known to interfere with BRD4, consequently
decreasing c-MYC expression in MSCs, which was evi-
dent in our results. The E2F transcription factor family
was among the highly downregulated groups in the gene
expression profile. We confirmed that E2F2 transcription
reduced upon JQ1 treatment of MSCs with qRT-PCR.
The E2F family plays a critical role in the regulation of
the cell cycle through transcriptional regulation of genes
involved in the G1 phase and DNA replication [41].
BRD2 has been shown to form a complex with E2F and
transactivates E2F responsive genes in NIH3T3 cells
[28, 29, 32, 41]. CCND1, CCNA, CCNE, and dihydro-
folate reductase were among the E2F responsive genes
[28, 29, 32]. Although G1 arrest, along with downregula-
tion of RB1 and stemness genes, has been reported in
senescent cells [42], our results showed downregulation
of senescence genes such as RB2, CDKN1A, CDKN2A,
and CDKN1B, suggesting that JQ1-induced arrest in
MSCs is not due to senescence.
(See figure on previous page.)
Fig. 7 Effect of JQ1 on the expression of pluripotency, WNT signaling, and differentiation genes as determined by qRT-PCR a–d and immunocytochemical
analysis e. a Pluripotent markers OCT4, KLF4, Nanog, and SOX2 were downregulated in MSCs treated with 100 nM JQ1 for 24 hours. b WNT signaling genes
CTNNB1, AXIN, FZD6, and LRP6 were upregulated and WNT2, FZD2 and FZD4 were downregulated in MSCs treated with 500 nM JQ1 for 24 hours and
5 days. c Osteogenic markers COL1 and RUNX2, chondrogenic markers COL2 and SOX9, and neurogenic marker Nestin were downregulated in MSCs treated
with 500 nM JQ1 for 24 hours. d Neuronal markers TUJ1, CCL5, INA and SMURF2 were upregulated in MSCs treated with 500 nM JQ1 for 24 hours and
5 days. e TUJ1 and MAP2 proteins were expressed in MSCs treated with 500 nM JQ1 for 5 days. Images acquired at 10× magnification. f Zoomed-in
merged image as shown in e. *p ≤0.05. Ctrl control, DAPI 4′,6-diamidino-2-phenylindole, JQ1 (S)-tert-butyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate
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Since JQ1 resulted in cell cycle arrest in MSCs, we
further investigated whether JQ1 induced apoptosis as
reported in cancer cells. Flow cytometric analysis also
showed no significant increase in Annexin V-positive
cells, suggesting that JQ1 did not induce apoptosis in
MSCs. To further confirm that JQ1 did not exert an
apoptotic effect in MSCs, transcriptional levels of BCL2,
BIM, Caspase 8, and Caspase 9, which play critical roles
in controlling the apoptotic pathways, were determined
by qRT-PCR. Even though JQ1 caused a significant
downregulation of BCL2, an antiapoptotic marker, ex-
pression of proapoptotic genes Caspase 8 and Caspase 9
were also downregulated, while no significant change in
the expression of BIM was detected. Western blot ana-
lysis also revealed significant downregulation of Caspase
8 but little change in the expression of Caspase 9, which
is consistent with the qRT-PCR analysis as discussed.
These results suggested that MSCs did not undergo
apoptosis when they were subjected to JQ1 treatment.
Stem cells have been reported to express several self-
renewal markers, including OCT4, Nanog, KLF4, and
SOX2 [43–47]. Our microarray and qRT-PCR data showed
that JQ1 treatment of MSCs led to downregulation of
OCT4, Nanog, KLF4, and SOX2, suggesting that BET pro-
teins play an essential role in the self-renewal of MSCs.
Since signaling pathways are known to play an important
role in differentiation processes, we investigated whether
WNT signaling was involved in self-renewal and differenti-
ation of stem cells [48]. Microarray analysis of the tran-
scripts from JQ1-treated MSCs indicated differential
expression of WNT-related genes. Further analysis of tran-
scripts of JQ1-treated cells by qRT-PCR revealed downreg-
ulation of WNT2, FZD2, and FZD4 and upregulation of
FZD6, LRP6, CTNNB1, and AXIN. These observations sug-
gest that the WNT pathway is turned off and differentiation
of MSCs is induced by JQ1. This is in partial agreement
with a previous report where downregulation of WNT2,
FZD2, and FZD4 and upregulation of CTNNB1 was in-
volved in neural differentiation of human adipose-derived
stem cells [49]. Taken together, these observations sug-
gested that JQ1 modulates WNT signaling, which is known
to be involved in self-renewal and differentiation of MSCs.
It has been proposed that BET proteins exert a dual
function where they act as coactivators for cell cycle genes
and corepressors for specific differentiation markers [1].
Therefore, we investigated the transcriptional expression
of lineage-specific differentiation markers. Among all of
the investigated differentiation markers, only TUJ1, CCL5,
INA, and SMURF2 were upregulated, which are neuronal
lineage-specific markers [50–52]. Although these data
showed modulation of suggested neuronal markers, this
alone is not sufficient to implicate JQ1 in neural/neuronal
differentiation. Nevertheless, the results indicate the
harmful effects of JQ1 on MSCs by modulating not only
the WNT signaling but also the genes involved in the dif-
ferentiation. Moreover, significant upregulation of genes
such as TNF, CCL5, and ICAM1 is interesting as observed
by microarray analysis because these genes have been
reported to be important for leukocyte recruitment and
cell adhesion [53, 54], suggesting that JQ1 treatment of
MSCs may have implication in tumor progression in situ.
Our results clearly showed that JQ1 inhibited MSC
growth by influencing important cellular processes includ-
ing cell cycle, signal transduction, and differentiation. In
addition, genes involved in self-renewal, DNA replication,
and mitosis were downregulated. JQ1 is likely to exert a
similar effect on MSCs derived from other adult sources
such as bone marrow MSCs. Interestingly, recently
published reports showed antioxidant activity of JQ1 and
its ability to block memory in mice [55, 56]. Therefore,
further studies are needed to clarify the molecular mech-
anism of action of the BET proteins in MSCs. Since JQ1
can inhibit all BET proteins, and a redundancy in the BET
proteins function has been proposed, additional investiga-
tion would help in elucidating which one of the BET
proteins is responsible for the transcription of genes
involved in MSC cell cycle regulation.
Conclusion
Overall, this study revealed harmful effects of JQ1 and
possibly other members of the thienodiazepine class on
growth, self-renewal, and cell cycle progression of MSCs.
The use of this class of BET inhibitors as anticancer
agents should therefore be more carefully evaluated before
their use for cancer therapy. Furthermore, our studies
provided a promising model to supplement animal studies
to investigate the safety of anticancer agents or drugs. This
is a simple and inexpensive system compared with animal
models and could provide results and predictions directly
applicable to humans. These findings are likely to have
implications in stem cell biology, cancer therapy, and re-
generative medicine and provide a basis for future studies.
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